Amgen beats Street

Amgen Inc. (NASDAQ:AMGN) reported 2Q10 adjusted diluted EPS of $1.38, beating by $0.08 the Street's estimate of $1.30 and up 7% from $1.29 in 2Q09. Revenues for the quarter were $3.8 billion, up 2% from $3.7 billion in the prior year's quarter and above the Street's estimate of $3.7 billion. Amgen said it now estimates its 2010 revenue to be slightly below $15.1 billion, down from $15.1 billion-$15.5 billion, due to a weaker euro. Amgen continues to expect full-year EPS at the lower end of its guidance range of $5.05-$5.25. ...